
Richard Ridinger resigns from CEO position at Lonza causing shares to plummet
pharmafile | January 30, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â CEO, Lonza, Marc Funk, Richard Ridinger, SwitzerlandÂ
Richard Ridinger, the CEO of Swiss biotechnology firm Lonza Group, will step down from his position in March of this year.
The 60 year old CEO will remain with the company until the end of April and will be available to Lonza as an advisor until the end of 2019. However he will leave his role on 1 March.
Ridinger will be replaced by the company’s current President and COO Marc Funk, who joined the firm in 2008. Before joining Lonza, Funk had previously acted as Head of Corporate Law at German-firm Merck Serono. Funk also acted as Co-CEO at the Illinois-based biotech Geneprot.
Ridinger has overseen a period of significant growth since joining the firm in 2012. Stocks in the firm plummeted on the news of Ridinger’s resignation.
Prior to joining Lonza, Ridinger served as head of Care Chemicals at Cognis Benelux BV from 2001 to 2006 and as an Executive Vice President of Care Chemicals at BASF.
Related Content

Switzerland’s Basel Region Crowned ‘Europe’s Top Destination to Launch a Drug Device Company’, According to Pharmapack Report
 Pharmapack Europe: ‘Basel the best location for drug device innovation in Europe thanks to combination …

Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …

Lonza to acquire Synaffix to strengthen ADC development
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has …






